Publications

Publications

Development of a test that measures real-time HER2 signaling activity in live breast cancer cell lines and primary cells. 

Huang, Y., Burns, D., Rich, B., MacNeil, I., Dandapat, A., Soltani, S., Myhre, S., Sullivan, B., Lange, C., Furcht, L., Laing, L.

BMC Cancer.  2017 March 17:199

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormal amplified HER2 signaling activity.  

Huang, Y., Burns, D., Rich, B., MacNeil, I., Dandapat, A., Soltani, S., Myhre, S., Sullivan, B., Furcht, L., Lange, C., Hurvitz, S., & Laing, L.

Oncotarget. 2016 Oct 5;7(48) 78577-78590

Abstracts and Posters

2017 San Antonio Breast Cancer (SABCS)

Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit from anti-HER2 therapy

Lance G Laing, David J Burns, Ian A MacNeil, Benjamin E Rich, Sajjad M Soltani, Samantha Myhre, Brian F Sullivan

2017 American Society of Clinical Oncology (ASCO)

Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study.

Laing, L., Burns, D., Huang, Y., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Sullivan, B.

Journal of Clinical Oncology 2017 35 _suppl, e23203

2017 Miami Breast Cancer Conference – Miami, FL

Inhibition of abnormal HER2-driven signaling by two HER2 targeted antibody drugs tested ex vivo in live primary HER2- breast cancer cell samples and HER2+ cell lines Abstract: #459.

2016 SABCS – San Antonio, TX

Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity.

Laing, L., Burns, D., Huang, Y., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Sullivan, B. [P4-12-06]

Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-06.

2016 SABCS – San Antonio, TX

New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy.  

Laing, L., Burns, D., Huang, Y., MacNeil, I., Rich, B., Soltani, S., Myhre, S., Sullivan, B. [P6-07-14]

Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-14.

2014 American Society of Clinical Oncology (ASCO)

Profiling of signaling pathways in live tumor cells to assess drug mechanism of action: A method to predict drug efficacy in a patient  [e11583] , American Society of Clinical Oncologists 201.

Laing, L., Huang, Y., MacNeil, I., Rich, B., Greeno, E.

Journal of Clinical Oncology 2014 32:15_suppl, e11583-e11583

2014 American Society of Clinical Oncology (ASCO)

Dynamic real-time signaling profiles of live primary cells characterize the response of PI3K and MAPK pathways in HER2+ breast cancer cells to attenuation with lapatinib: Tests of reproducibility of method.

Laing, L., Huang, Y., MacNeil, I., Rich, B., Greeno, E. [e11597]

Journal of Clinical Oncology 2014 32:15_suppl, e11597-e11597